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Abstract—The emerging area of computational pathology
(CPath) is ripe ground for the application of deep learning (DL)
methods to healthcare due to the sheer volume of raw pixel
data in whole-slide images (WSIs) of cancerous tissue slides.
However, it is imperative for the DL algorithms relying on nuclei-
level details to be able to cope with data from ‘the clinical
wild’, which tends to be quite challenging. We study, and extend
recently released PanNuke dataset consisting of ∼200,000 nuclei
categorized into 5 clinically important classes for the challenging
tasks of segmenting and classifying nuclei in WSIs [1]. Previous
pan-cancer datasets consisted of only up to 9 different tissues and
up to 21,000 unlabeled nuclei [2] and just over 24,000 labeled
nuclei with segmentation masks [3]. PanNuke consists of 19
different tissue types that have been semi-automatically annotated
and quality controlled by clinical pathologists, leading to a dataset
with statistics similar to ‘the clinical wild’ and with minimal
selection bias. We study the performance of segmentation and
classification models when applied to the proposed dataset and
demonstrate the application of models trained on PanNuke to
whole-slide images. We provide comprehensive statistics about
the dataset and outline recommendations and research directions
to address the limitations of existing DL tools when applied to
real-world CPath applications.
I. INTRODUCTION
The success of convolutional neural networks (CNNs) in
computer vision (CV) algorithms applied to natural image
and medical imaging tasks can generally be attributed to the
availability of large datasets and computing power [4]–[8].
Given the excellent performance on these tasks, measured by
an average metric evaluated over a large dataset, CNNs have
sparked hope and promise in healthcare applications [9], [10].
The field of computational pathology (CPath) is witnessing
a rapid rise in the research and development of deep learning
(DL) models for quantitative profiling of spatial patterns in
digitized whole-slide images (WSIs) of cancerous tissue slides
that are rich in content and information [11]. Numerous studies
have demonstrated the potential of deep learning (DL) models
in detecting cancer, classifying tissue, identifying diagnosti-
cally relevant structures and even inferring genetic sub-types
[10], [12]–[16].
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Fig. 1: Illustration of PanNuke label generation and verifica-
tion.
It would be fair to state that challenge contests have become
a popular mean for attracting attention to a particular dataset
or a task in medical imaging. In computational pathology,
for instance, a variety of deep CNNs for automated nucleus
segmentation have been developed on a dataset consisting of
21,623 nuclei in a total of 32 images of the size 1, 000×1, 000
pixels and released as part of the MoNuSeg challenge contest
[2]. However, the use and validity of results in most challenge
contests is questionable due to the limited diversity [17].
PanNuke, released under the CC license is however a diverse
pan-cancer dataset that has undergone clinical quality control
(QC).
Second, CNN models applied to medical images are more
powerful than the datasets that we apply them to, these models
are known to suffer from over-fitting to surface statistical
regularities [18]–[21]. A model can obtain stronger inductive
biases (a set of assumptions that a model uses to predict on
a certain task) through multi-task learning, and therefore be
more robust in practice [22]. The current approach in com-
putational pathology is to train a model for a specific tissue,
or even just a specific disease sub-type classification. On the
other hand, we argue for a top-down algorithm development in
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2medical imaging i.e. develop general and user-friendly tools
that can easily be used by domain experts, and for bottom-
up approach for dataset creation for supervised learning. Far
too much medical imaging community’s effort is focused on
semi-supervised and unsupervised studies, however, these are
far from clinically applicable and would always under-perform
compared to supervised approaches trained on accurately
labeled ground truth data. Models trained on PanNuke, as we
demonstrate in Figure 3, could be used to assist detailed semi-
automatic labeling in 19 different tissues. The results of nuclei
detection and classification can be used for tissue pheno-typing
as demonstrated in Colon tissue by Javed et al. [13].
This work is motivated by the fact that publicly available
nucleus segmentation and classification datasets do not often
match the distribution of data in ‘the clinical wild’, as can be
seen in Figure 2 which shows the results of a nucleus detection
model [1] trained on the MoNuSeg challenge dataset [2]. It can
be observed that when the model is applied to a few images
that contain commonly found artifacts in clinical practice,
there are several false detections which could lead to incorrect
or misleading results in downstream CPath analysis. A similar
phenomenon has been demonstrated by Oakden-Rayner et
al. [23] in the literature and in a validation study of DL
models applied to radiology images where model performance
dropped significantly in a real-world environment [24].
The main contributions of this work are summarized as
below:
• We present PanNuke1, the largest and the most diverse to
date dataset for nucleus segmentation and classification,
that has been annotated in a semi-automated manner and
quality-controlled by clinical professionals;
• We accelerate the process of verification (i.e., quality
control) by the clinical professionals by incorporating
NuClick [25] during the generation of segmentation
mask, as shown in Figure 1;
• We evaluate the performance of several nucleus segmen-
tation models on PanNuke, which is 26 times larger
in terms of unique 224×224 training patches than the
previous MoNuSeg challenge dataset [2];
• We provide a full schema that could be used by the
algorithm developers and that applies to other tissues
not included in the PanNuke dataset. We show that
segmentation models trained on PanNuke generalize to
tissues like brain that were not part of the dataset.
• By releasing PanNuke to the broader CV research com-
munity, we encourage the community to develop new DL
models to help push forward clinically relevant research.
These are not the only goals of this research. In fact, we
hope to draw attention to the established tendencies in the
field and their systemic impact on the risks as well as positive
outcomes of CV in the healthcare domain and its progress.
In the following sections, we describe the relevant literature,
our methodology, the quality of the automatically generated
nucleus segmentation masks, provide qualitative and quantita-
tive analysis of the dataset and it’s significance. Finally, we
1Download dataset here: https://jgamper.github.io/PanNukeDataset
Fig. 2: 1st column: A selection of visual fields from the Kumar
dataset et al. [26]. 2nd-3rd columns: A selection of visual
fields in PanNuke with output of a detector trained on [26]
overlaid on the images. False positives (shown as red dots, as
opposed to true positives as yellow dots) are clearly visible
in the areas of burnt tissue, blur or other tissue processing or
scanning artifacts.
evaluate the performance of existing approaches to nucleus
segmentation and classification.
A. Related Work
Recent work in computational pathology has demonstrated
that nuclear features can be effectively used for: cancer
scoring, bio-marker discovery, cancer recurrence prediction
as well as for predicting treatment effectiveness [27]–[30].
However, these are small sample size studies limited to a
single tissue, and are focused on commonly studied tissues
such as lung, breast, prostate and colon, due to the lack of
data for other tissues. Javed et al. [13] demonstrated that
inferred nuclear categories may help in classifying different
tissue phenotypes within colon slides by constructing a graph
of nuclei connections and detecting communities. By training
models on PanNuke and applying them to WSIs at scale, these
studies could be extended to 19 different tissues.
Closest in scale and real-world proximity to PanNuke is the
work of Hosseini et al. [31], who have provided multi-category
patch-level annotations. Due to having only patch annotations,
Chan et al. [32] pursued semantic segmentation using class
3Fig. 3: Visualisation of applying nuclei segmentation and classification network trained on PanNuke to unseen whole-slide
images. Top row: Cervix tissue, with a visible differentiation between tumor and other tissue types. Bottom row: Prostate
tissue.
activation maps that significantly under-performed pixel-wise
supervised models on the GlaS challenge dataset [33]. Across
the board, large CPath studies have been somewhat limited
by the lack of granular annotations [4], [34], [35]. However,
PanNuke provides pixel-level boundary annotation for every
individual nucleus, a building block of any organ’s tissue.
As a result, using models trained on PanNuke further semi-
automatic labeling of tumor or tissue phenotypes is feasible
[13] (Figure 3).
II. THE PANNUKE DATASET
In the sections below, we describe our methodology, discuss
the quality of the automatically generated nucleus segmenta-
tion masks and provide qualitative and quantitative analysis
of the dataset and its significance in algorithmic and practical
terms.
A. Dataset Generation
Data Labeling: First, we aggregated a set of publicly
available nucleus classification and detection datasets to create
an initial dataset for semi-automatic ground truth generation.
For this, we trained a fully convolutional neural network
(FCNN) for nucleus detection using 4 publicly available
datasets: Kumar [26], CPM2017 [37], 15 visual field from
TCGA [38] that we have labeled ourselves, and a dataset of
bone marrow visual fields [39]. Kumar is a dataset of 16 visual
fields consisting of 7 different tissue types (liver, prostate,
kidney, breast, stomach, colorectal and bladder) and CPM2017
is a dataset of 64 visual fields of 4 cancer types (glioblastoma,
low grade glioma, head neck squamous cell carcinoma and
non-small cell lung cancer). Therefore, in total we initially
utilize 106 visual fields. We then trained a convolutional neural
network on nuclei CNN patches (see Figure 4 for illustration)
extracted from the datasets described in Table I2, that were re-
labeled according to the PanNuke categories. The schema for
nuclei categories will be described in the subsequent sections.
Using the CNN, we exhaustively classified all of the detected
nuclei in the above mentioned datasets, which were then
verified by a team of expert pathologists. After, we sampled
2,000 visual fields from more than 20,000 WSIs in 19 different
tissues obtained from TCGA and also from a local hospital.
Random sampling of visual fields allowed us to address the
selection bias present in available public datasets, in fact visual
fields with common clinical artifacts demonstrated in Figure
2 are from the final PanNuke dataset.
When sampling visual fields of tissue from WSIs, the tissue
may have been originally frozen or paraffin embedded and also
the WSIs may have been scanned with a maximum resolution
of either 20× or 40×. We re-sized the selected visual fields so
that all images were at 40× resolution and we excluded frozen
tissue from the study. We then re-sampled the visual fields
so that the images present in the dataset were diagnostically
relevant and also reflected the true variation of tissue in each
organ. We also ensured that artifacts remained in the dataset
because they are inevitable when facing data in the ‘clinical
2BrestPathQ source: https://breastpathq.grand-challenge.org/
4TABLE I: Data used to initialize semi-automatic labeling. In bold PanNuke nuclei categories.
PanNuke Nuclei Categories
Epithelial Inflammatory Neoplastic Dead Connective Tissue Non-nuclei Total
MoNuSeg 836 1,698 5,927 0 906 0 9,367
Colon Nuclei 7,544 6,003 4,685 2,547 4,468 0 25,247
BreastPathQ 0 2,139 9,802 0 0 0 11,941
Nuclei Attribute 0 0 0 0 0 500 500
Total 8,380 9,840 20,414 2,547 5,374 500 47,055
Fig. 4: Ground truth labels and segmentation masks verified by pathologists alongside model prediction for bladder tissue
visual field. FCNN patch represents a 224×224 patch commonly used for training fully convolution segmentation models,
right below it is a patch used by [36] for training a CNN to classify each individual nucleus.
wild’.
We then proceeded to Part A of annotation process, as
illustrated in Figure 1. Iterating 7 times, where after each
stage pathologists would verify and re-label the detected and
classified nuclei dots. In each stage, the FCNN detection
and classification model was trained with the new collected
annotations to provide better predictions for next iteration.
Eventually, this leads to a dataset of 481 visual fields with
a total of 205,343 exhaustively annotated nuclei, verified by
domain experts.
Mask Generation: For the final version of PanNuke we
used NuClick [25]. Nuclick is a method that enables accurate
segmentation mask generation from a single point. Therefore,
this enables us to produce many segmentation masks at a
relatively low cost and also eases the verification process
because only a single point is required from the pathologist,
as opposed to the entire mask. Figure 5 presents a selection
of masks generated by a segmentation FCNN, as well as by
NuClick. In the first row, the FCNN has mistaken pigment in
skin tissue as nuclei. However, because NuClick is conditioned
on verified nuclei dots, only nuclei pixels are segmented. Also,
the FCNN frequently misses elongated nuclei compared to
NuClick and often struggles to segment nuclei with indistinct
boundaries, as pictured in the second column and third row.
Finally, the last row shows that FCNN only segments the
nucleolus, whereas NuClick segments the entire nucleus.
Using the proposed semi-automatic pipeline, we generated
and verified 205,343 nuclei from more than 20,000 WSIs.
Some examples of generated ground truth are depicted in the
Figure 6.
B. Dataset Description and Statistics
Dataset Schema: For the purpose of this work, we derived
a schema in Table II for generating nuclei labels that is
clinically sound and is shared across the 19 tissues within the
dataset. The proposed schema provides insight into how we
categorized all nuclei and can be used to appropriately sub-
type nuclei in future studies. Our schema is consistent with the
nuclei categories used in previous tissue-specific studies [3],
[31], [36] and therefore work previously developed on these
datasets can be seamlessly extended to PanNuke. We split the
cell types between Neoplastic and Non-neoplastic cells.
Neoplasm (’new growth’) includes any tumor, malignant
or benign. It includes carcinomas, sarcomas, melanomas,
lymphomas, etc. These are all tumors but originate from
different cell types: carcinomas from epithelial; sarcomas from
soft tissue; melanomas from melanocytes; lymphomas from
lymphoid cells and so on. As such, all abnormal cells in
PanNuke are labeled as Neoplastic. s Non-neoplastic covers
everything else, from normal to inflammatory, infections, de-
generative, metaplastic, atypia etc. For the purpose of this ex-
ercise, atypia is under the heading of non-neoplastic, although
some researchers may argue that they have clonal changes
and potential for turning into neoplastic cells. As such, non-
neoplastic labels in PanNuke are: epithelial; connective/soft
tissue cells; inflammatory and dead cells. Inflammatory cells
include lymphoid and macrophage cells in PanNuke.
5Fig. 5: Left column: Pathologist verified nuclei dots; Middle:
CNN generated segmentation masks; Right: NuClick gener-
ated segmentation masks and subsequently verified. Color dots
are consistent with the legend in Figure 4.
Dataset Statistics: In general, most nuclei types that we
provide in our schema are represented in all tissues considered
in PanNuke, but the distribution of the nuclei count per class
may vary from tissue to tissue. This can be seen in Figure 7,
where we observe that the total nuclei count per tissue as well
as per class changes between tissue types.
In our experience, a pathologist when annotating nuclei
frequently refers to the WSI at a lower resolution, to observe
the surrounding structures. Seminal work in automatic nuclei
classification by Sirinukunwattana et al.et al. [36] considered
only nuclear patches when performing classification (CNN
patch in Figure 4), or small image patches containing a few
nuclei in the more recent work using fully convolutional
networks (FCNN patch in Figure 4) - both approaches have
demonstrated high accuracy on average. What does it mean
for us? Either that pathologist overfits given the surrounding;
or that looking at a nuclear patch to classify nuclei is not
sufficient; or an average accuracy metric is not a clinically
relevant measure of algorithmic performance. Recently Oak-
den et al. [40] has demonstrated effects of hidden stratification
in medical imaging, i.e. when labels used in CV or ML
studies do not represent clinical reality, and that average per-
formance is not a strong measure of applicability. As Figure 4
demonstrates hidden stratification is also present in histology,
TABLE II: Nucleus classification schema for computational
pathology.
# Level-1 Level-2 Level-3
1
Epithelial Neoplastic
Malignant˜
2 Benign˜
3 Non neoplastic
4
Connective/
Soft tissue cells
Fibroblasts
5 Endothelial
6 Myo-fibroblasts
7 Fibers
8 Adipocytes
9
Lympho-reticular
cells
Trombocytes
10 Erythrocytes
11
Leukocytes
Eosinophils
12 Basophils
13 Neutrophils
14 Lymphoid cells Plasma cells15 Lymphocytes
16 Macrophages/Histiocytes
17 Mast cells
18
Nervous system
cells
CNS
Oligo-
dendrocytes
19 Microglia
20 Astrocyte
21 Ependymalcells
22 PeripherialNervous
Schwann
cells
23 Ganglia Ganglioncells
24 Dead Apoptotic25 Necrotic
if one is to use nuclei classification for downstream tasks.
Carcinoma (malignant epithelial tumor/neoplasm) can be non
invasive (i.e. in situ) or invasive. They are both composed
of malignant cells but in situ is still ”bounded” by either
basal cell layer/myoepithelial layer or basement membrane
(depending on organ site) hence called non-invasive. Invasive
carcinomas have lost basal cells/myoepithelial cells. So in
theory, non invasive cancer should have no or low potential
for lympho-vascular space invasion, distant metastases and
similar (i.e. they should have better prognosis than or may
not need as radical treatment as invasive carcinomas). For this
specific image, for example, it would appear that this tumor
cells are ’bounded’ by basement membrane cells (Figure 4
Ground Truth). While FCNN based model (Figure 4 Predic-
tion) classifies epithelial cells surrounding tumor cells as part
of connective tissue category, evidently due to their shapes and
the tendency of deep models to look for simplest association
that describe the relationship between the feature and target
on average [18], [21]. Notably, these cells would be unlikely
correctly classified by ANY algorithm. We either need to
incorporate prior knowledge about the underlying mechanisms
in the tissue in order to solve these tasks as precisely as a
pathologist, or acquire multiple, similar cases and train on
substantially larger image sizes than FCNN patch.
These are just a few examples of cases which are difficult to
simply classify/diagnose as neoplastic or non-neoplastic. Other
challenging examples could not be included given the limited
space, but in clinical practice these cases are more frequent as
compared to how they are portrayed in the AI/digital pathology
literature.
6Fig. 6: Example of PanNuke patches and their ground truth annotations overlaid.
Fig. 7: A comparative plot of class distributions per tissue.
Numbers in parenthesis represent the total number of nuclei
within that category or tissue type.
III. PERFORMANCE BENCHMARKS
Previous nucleus segmentation datasets provided visual
fields and therefore patch extraction between different methods
for training and testing is not standardized. For PanNuke
we pre-extract patches and split into 3 randomized training,
validation and testing folds for a fair model comparison. For
every fold we split every tissue into three sections by ensuring
that each contains an equal portion of the smallest class within
it (refer to Figure 7). Here, we apply recent and well known
models on PanNuke to create a benchmark for further research
using this dataset.
A. Baseline Models
There are not an abundance of models that perform si-
multaneous segmentation and classification and therefore we
adapt several top-performing instance segmentation models
so that they additionally classify each nucleus. We quantified
the performance of 5 models on PanNuke: DIST [42] which
utilizes the distance map of instances as the target and we add
another branch for semantic pixel-wise classification; Mask-
RCNN [43] which is a state-of-the-art instance segmentation
network for natural images; U-Net [44] which was proposed
for segmentation of EM images and is widely used for
7Fig. 8: Brain tissue visual fields from Qureshi et al. [41] and predictions overlay using HoVer-Net trained on PanNuke.
medical image segmentation and Micro-Net [45] which was
proposed for nuclear and gland segmentation. HoVer-Net [3],
which uses the concept of horizontal and vertical distance
maps, does not need to be adapted as it inherently performs
simultaneous nuclear instance segmentation and classification.
Note, that each of the above mentioned models performed
extensive comparison with competing segmentation methods
and therefore we focus on the best performing models.
In addition to the segmentation models, we also imple-
mented a detection-based U-Net, similar to the model proposed
by Xie et al. [46], where the detection maps for each class
were used as the target for training the network. Specifically,
the detection map for each nucleus was converted to a 2D
Gaussian centered at the true nucleus centroid.
B. Evaluation
Instance Segmentation: To quantify the instance segmen-
tation performance of each of the models trained on PanNuke,
we use panoptic quality (PQ) [3], [47]. An in depth discussion
as to why we choose to utilize PQ over other recently used
metrics for nucleus segmentation is discussed by Graham et
al. [3]. Specifically, we used multi-class PQ (mPQ) which is
the average of PQ for all positive classes and binary PQ (bPQ)
which is the segmentation quality regardless of classes. The
IoU threshold for calculating PQ is set to 0.5.
To provide insight into how each model performs for
different types of nuclei, in Table III, we report mPQ and
bPQ for all 19 tissue types separately. We observe that HoVer-
Net achieves the best performance for most tissue types and
is reflected by the greatest average score over all tissues for
mPQ and bPQ. We also report PQ for each type of nucleus
in Table IV. Dead cells obtain a very low PQ for all models
because these nuclei are very small and therefore achieving an
IoU>0.5 (PQ criterion for true positive) is difficult. In some
cases, distinguishing between neoplastic and non-neoplastic
nuclei proved to be challenging, yet it must be emphasized
that this also can be a challenging task for the pathologist,
where they often need to assess contextual information before
confirming the the type of nucleus. As deduced from Figure 7
class imbalance may also lead to poor performance for dead
cell and non-neoplastic classes.
Detection: In order to allow cross comparison with detec-
tion models (as opposed to segmentation), we reported the F1,
precision and recall for the overall detection quality in Table V.
Here, a true positive was considered as a detection within 12
pixels of the labeled centroid [36]. We also calculated. In order
to report the detection performance for segmentation models,
we extracted the centroids of each instance as detection points.
We observed that segmentation models generally performed
better than the detection model. We hypothesize that this
is because the detection-based model does not incorporate
boundary information.
C. Generalisation to other tissues
We speculated that models trained on PanNuke would likely
generalise to other tissues and applied the best performing
model to brain tissue as demonstrated in Figure 8. Within
this tissue, the model was able to perform a successful
segmentation of all nuclei, but found it challenging to predict
the correct nuclear categories. The algorithm trained with
PanNuke performs favourably for segmentation of nuclei for
the 4 images in Figure S3 (DICE value 0.796, mPQ 0.28 and
bPQ 0.51) from a completely unseen source (Germany) and
tissue type (brain), as compared to the tissue-wise average in
Table 3.
8TABLE III: Average mPQ and bPQ across three dataset splits. We also provide the standard deviation (STD) across these
splits in the final row.
DIST Mask-RCNN U-Net Micro-Net HoVer-Net
mPQ bPQ mPQ bPQ mPQ bPQ mPQ bPQ mPQ bPQ
Breast 0.3149 0.5452 0.3431 0.5538 0.3404 0.5528 0.3983 0.6016 0.4259 0.6425
Colon 0.2500 0.4460 0.2631 0.4537 0.2760 0.4607 0.3084 0.4941 0.3551 0.5505
Bile duct 0.2854 0.5242 0.2927 0.5432 0.2960 0.5551 0.3533 0.6148 0.3754 0.6521
Esophagus 0.3285 0.5283 0.3712 0.5678 0.3338 0.5491 0.4114 0.5987 0.4402 0.6424
Uterus 0.2691 0.5246 0.2961 0.5588 0.2935 0.5487 0.3340 0.5821 0.3515 0.6426
Lung 0.2364 0.4955 0.2756 0.5111 0.2534 0.5158 0.3005 0.5564 0.3263 0.6242
Cervix 0.2618 0.5043 0.2858 0.5209 0.3132 0.5745 0.3299 0.5897 0.3712 0.6616
HeadNeck 0.2666 0.4707 0.3231 0.5162 0.3085 0.5254 0.3042 0.5065 0.3604 0.6002
Skin 0.2084 0.4958 0.2257 0.4902 0.2189 0.4965 0.2697 0.5678 0.2695 0.6196
Adrenal Gland 0.3005 0.5579 0.2985 0.5522 0.3101 0.5842 0.3663 0.6412 0.4009 0.6857
Kidney 0.2296 0.5441 0.2513 0.4791 0.2811 0.5825 0.3157 0.6213 0.3227 0.6639
Stomach 0.3036 0.5553 0.3517 0.5975 0.3484 0.6079 0.3661 0.6292 0.4186 0.6806
Prostate 0.3309 0.5418 0.3522 0.5789 0.3306 0.5615 0.3881 0.6049 0.4361 0.6601
Testis 0.2636 0.5516 0.3010 0.5325 0.3200 0.5881 0.3540 0.6263 0.3983 0.6793
Liver 0.2843 0.5817 0.3559 0.6084 0.3216 0.6164 0.3859 0.6630 0.3944 0.7129
Thyroid 0.2056 0.5489 0.2460 0.5580 0.2727 0.5750 0.3202 0.6429 0.3452 0.6904
Pancreatic 0.2872 0.5342 0.3138 0.5460 0.3135 0.5604 0.3676 0.6074 0.3912 0.6449
Ovary 0.3224 0.5289 0.3759 0.5784 0.3590 0.5523 0.3933 0.6012 0.4205 0.6379
Bladder 0.3695 0.5532 0.4530 0.5811 0.4530 0.6442 0.4816 0.6340 0.4730 0.6820
Average across tissues 0.2799 0.5280 0.3145 0.5436 0.3128 0.5606 0.3552 0.5992 0.3830 0.6512
STD across splits 0.0102 0.0075 0.0097 0.0096 0.0182 0.0086 0.0102 0.0035 0.0009 0.0003
TABLE IV: Average PQ across three dataset splits for each
nuclear category.
Neo Non-neo Inflam Con Dead
DIST 0.31 0.18 0.28 0.24 0.00
U-Net 0.34 0.17 0.26 0.27 0.04
Mask-RCNN 0.37 0.27 0.24 0.27 0.05
Micro-Net 0.40 0.32 0.29 0.30 0.04
HoVer-Net 0.44 0.30 0.35 0.35 0.05
IV. CONCLUDING REMARKS
In this paper, we presented a semi-annotated and quality-
controlled dataset with detailed boundaries and class labels
for 5 main types of nuclei for multiple different cancerous
tissue types. This work is motivated by the observation that
the use and validity of results in most challenge contests is
questionable due to the limited nature of challenge datasets
[17]. For example, even on ImageNet [48] (which happens
to be many orders or magnitude larger than [26]), there is
evidence of overfitting due to multiple-hypothesis testing in
architecture development [49]. In addition to selection bias in
the available datasets, results are reported on labels that do not
always meaningfully describe the variation within the popula-
tion. This work, while providing a significant contribution in
modeling and dataset size compared to any previous work, is
only a small step in the direction of safe and robust application
of CV in CPath. Similarly to Esteva et al. [50], we offer a
careful treatment of PanNuke labels, discuss the real world
complexities of the task and offer schemas that researchers
can use to push nuclei classification research further.
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APPENDIX
A. PanNuke labelling schema
The categories in PanNuke consist of: neoplastic, epithelial,
connective tissue, inflammatory and dead cells. These labels
can be grouped into either neoplastic or non-neoplastic cell
types. However, as Table A1 shows, non-neoplastic can cover
everything from normal to inflammatory conditions, infections,
degenerative, meta-plastic, atypia and dysplasia. In Figure 9
we display a visual field from colon tissue where pathologists
identified dyspalstic epithelial cells. Here, dysplasia specifi-
cally refers to a pre-neoplastic stage, where it has not yet
Fig. 10: Visual field extracted from adrenal gland tissue and
its ground truth on the right.
TABLE A1: Breakdown of neoplastic and non-neoplastic cell
types and sub-types.
Plasticity Sub-types
Neoplastic Malignant TumorsBenign Tumors
Non-neoplastic
Normal
Hyperplastic
Hypertrophic
Meta-plastic
Inflammatory
Degenerative
Infection
Atypia/Dysplasia
developed into a benign or malignant tumor. Therefore, these
colon tissue cells would be labeled as epithelial. Neoplastic
labels in PanNuke specifically correspond to benign and ma-
lignant tumor cells.
More than 2,000 visual fields from a variety of tissues have
been reviewed when developing PanNuke. A major challenge
for pathologists during the semi-automatic verification process
in PanNuke was the necessity to refer back to the original
WSIs to label the categories in the visual field. In Figure 10,
parts of this image can be marked straightforwardly as stroma
and inflammatory cells, but classifying the rest of this image
is more challenging. For instance, it may represent retraction
artifact or neoplasm, specifically pheochromocytoma. Once the
WSI was viewed, this area turned out to be neoplastic, i.e.
pheochromocytoma. This reiterates the point made in the main
text that algorithms are trained on image patches and therefore
do not contain the contextual information present in the WSI.
This is further exacerbated by the distribution of the nuclei
size. Nuclei from the connective tissue are noticeably larger
- however their shape and size do not directly indicate its
category, as presented in Figure 11. This exemplifies the
challenge of classifying between epithelial and connective cell
categories. Neoplastic cells tend to be far larger on average
compared to any other category. Besides the cell size variabil-
ity per category within the tissue type, there is a significant
difference in distribution of size between the tissues. Epithelial
cells in particular vary in size between tissues- this emphasizes
the importance of collecting labeled datasets across different
tissue types.
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Fig. 11: Nuclei size distribution per class within every tissue type in PanNuke. Nuclei size is measured by pixel count within
a segmentation mask for a particular nuclei.
